Business Context and Reporting Period
Company: NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: NeOnc is a clinical-stage biopharmaceutical company developing novel drug delivery technologies for central nervous system diseases, specifically intracranial malignancies. Lead candidates include NEO100 (intranasal delivery for glioblastoma) and NEO212 (oral chemical conjugate). The Company operates as a single segment: Biotechnology research.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 (Note: $39,990 reclassified to R&D reduction) |
| Net Loss | $(23,059,976) | $(38,006,186) |
| Net Loss Per Share (Basic/Diluted) | $(0.96) | $(2.04) |
| Total Operating Expenses | $21,125,549 | $37,608,876 |
| Research & Development Expenses | $3,936,009 | $1,635,564 |
| Stock-Based Compensation | $8,384,311 | $20,923,850 |
| Advisory Fees (Related Party) | $4,946,575 | $11,737,806 |
| Cash and Cash Equivalents (End of Period) | $1,973,420 | $125,039 |
| Net Cash Used in Operating Activities | $(11,756,954) | $(10,964,226) |
| Net Cash Provided by Financing Activities | $13,671,645 | $11,024,372 |
| Total Liabilities | $23,761,103 | $20,331,363 |
| Accumulated Deficit | $(135,814,631) | $(88,614,631) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $14.9 million compared to the prior year period, primarily driven by a significant decrease in stock-based compensation and advisory fees.
- Stock-Based Compensation: Decreased by $12.5 million year-over-year. The prior year included a large catch-up expense upon the Company's Nasdaq listing. The current period included a $4.8 million charge for the acceleration of vesting for 734,356 shares in April 2026.
- Advisory Fees: Decreased by $6.8 million. The prior year included a one-time $11.3 million fee upon the Nasdaq listing. Current period fees relate to capital financing arrangements.
- Research & Development: Increased by $2.3 million due to the addition of clinical trial sites for NEO100 and NEO212, increased manufacturing activity, and the initiation of a pediatric trial for NEO100-03.
- Liquidity Position: Cash balances increased significantly from $58,729 at year-end 2025 to $1,973,420 at June 30, 2026, following successful financing activities.
- Debt Repayment: The Company repaid a convertible promissory note in full in January 2026, eliminating the $5.95 million liability present at the end of 2025.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity
The Company has raised substantial doubt regarding its ability to continue as a going concern for one year from the issuance date. While cash balances improved to ~$2.0 million, management does not believe current resources are sufficient to fund operations for the next 12 months without additional financing. The Company is actively pursuing additional capital through its Equity Purchase Agreement, Line of Credit, and potential equity offerings.
Recent Financing Activities
- PIPE Financing: Raised approximately $15.1 million through the sale of common stock and warrants in the first half of 2026.
- Series A Preferred Stock: Issued 6,000 shares in June 2026 for gross proceeds of $5.0 million. An embedded derivative liability of $1.65 million was bifurcated and recorded.
- Equity Line of Credit: Sold 76,648 shares under the agreement with Mast Hill Fund, LP for net proceeds of $663,727.
Risks and Contingencies
- Going Concern: Substantial doubt exists regarding the ability to continue operations without further capital raises.
- Unremitted Tax Withholdings: The Company has accrued $9.45 million in restricted stock tax withholding obligations that have not been remitted to taxing authorities, resulting in accrued penalties and interest.
- Litigation Settlement: A $4.38 million settlement payable to Orient EuroPharma Co., Ltd. remains outstanding as of June 30, 2026.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including segregation of duties and related party transaction tracking, which were not fully remediated as of June 30, 2026.
Investor Verification Checklist
- Going Concern Status: Verify the timeline and probability of securing additional financing to cover the 12-month operating runway.
- Tax Liability: Confirm the plan and funding source for remitting the $9.45 million in accrued tax withholdings and associated penalties.
- Litigation Exposure: Assess the impact of the unpaid $4.38 million settlement to Orient EuroPharma on future cash flows and potential legal escalation.
- Internal Controls: Review the progress of remediation efforts for the identified material weaknesses in financial reporting controls.
- Derivative Liability: Monitor the fair value changes of the $1.65 million derivative liability associated with the Series A Preferred Stock, which impacts net income.
- Related Party Transactions: Scrutinize the $4.95 million advisory fee paid to AFH Holdings (related to the CEO) and the terms of the 2.5% market cap fee structure.